Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helleborus niger extract (Hiscia) is a standardized aqueous botanical preparation developed by the Hiscia Institute (Society for Cancer Research) for use in integrative and anthroposophic oncology. Derived from the Christmas rose, the extract contains a complex mixture of bioactive compounds, including cardiac glycosides (such as hellebrin), steroidal saponins, ecdysteroids, and γ-lactones. These components are thought to work synergistically to induce apoptosis and exert cytotoxic effects on various malignant cells, including those from brain tumors, prostate cancer, and hematological malignancies. In clinical practice, it is typically administered via subcutaneous or intravenous injection as a complementary therapy alongside conventional treatments to modulate the immune response and inhibit tumor proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Helleborus niger extract (Hiscia).